http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-200829254-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb8875cbfb280adbfc20ef472664cc3e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-00 |
| filingDate | 2007-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d50e67075dceed81e91f1ffec3fe6ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_807f56cbde460664c504b6950b99394e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9c33db3774f3584b913af4ce883583e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09f128a669b736a5f54ecdcfb29e5d30 |
| publicationDate | 2008-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-200829254-A |
| titleOfInvention | The functions of lithospermate B salt for inhibiting cellular Na+/K+-ATPase activity |
| abstract | The present invention is directed to a method to inhibit the cell membrane Na+/K+-ATPase activity with Danshen extract, magnesium lithospermate B (MLB), and satisfies the need for an altemative medicine differing from cardiac glycoside without the danger of toxication. According to the preferred embodiment, the variations of Na+/K+-ATPase activity of cortex and cardiac cell membrane were monitored with increasing MLB concentrations. The result shows that Na+/K+-ATPase activity is repressed by MLB, which extracted from its source plant Danshen. The proportion phenomenon can determine that MLB is a Na+/K+-ATPase inhibitor. The preferred embodiment of the present invention, discloses MLB provides a mechanism similar to cardiac glycoside. The Na+/K+-ATPase activity is depressed when treated with various MLB concentrations and compared to cardiac glycoside, Another preferred embodiment of the present invention, discloses MLB provides positive effects of against cerebral hypoxia and cerebral infarct in lower dosage. Moreover, the lower dosage MLB has significant repress the cerebral infarct volume and size under a focal cerebral ischemia model. The result shows the MLB has a purpose to prevent and treat for the cerebral infarct caused by ischemia-reperfusion of ischemia stroke. That is, MLB is able to repress the Na+/K+-ATPase activity and is useful for cardiac stimulation, diuretic enhancement, heart failure cures, anti-anoxia, neurocyte apoptosis protection, apoplexy prevention and treatment, and so on. Mechanisms of above-mentioned effects are relative to the inhibition of Na+/K+-ATPase activity. Consequently, MLB is an equivalent to the cardiac glycoside and contributes to an alternative medicine different from cardiac glycoside to develop a pharmaceutical agent or functional food. It is to be understood that both the foregoing general description and the following detailed description are by examples, and are intended to provide further explanation of the invention as claimed. |
| priorityDate | 2006-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.